November 2014 Volume 10, Issue 11
Volume 10, Issue 11 | November 2014
November 2014
In this Issue
Editor's Focus
Clinical trials and tribulations
Conducting clinical trials in "developing nations" and other places that aren't part of the so-called First World has been great for some pharmas and biotechs in terms of cutting costs and increasing recruitment, but the cost benefits won't last foreverCommentary
Out of order: Regulator, go to heal
Is it time for Health Canada to give up on regulation of drugs and medical devices, following the lead of the U.S. FDA on that front and focusing on other public health duties for which it is better equipped?Success of new-generation metabolo-therapies in personalized medicine depends on measuring bioenergetic health
At the crossroads of understanding cell physiology, disease pathology and etiology is cell metabolism, which is widely known to be a common feature of these costly, debilitating and lethal diseases. In part because of this, The next decade will witness the release of a new class of drugs, known as “metabolo-therapeutics,” which will target metabolic pathways and the individual metabolites that are required for the maintenance of normal health.Q&A
Q&A: Celsus seeks to develop the anti-inflammatory drugs of the future
DDNews talks to Dr. Gur Roshwald, CEO of Celsus Therapeutics, about his company's proprietary drug technology platform and progress in the area of multifunctional anti-inflammatory drugsSpecial Reports
Special Report on Disease Modeling: So life-like
After decades of questionable results, are disease models turning a corner?Feature
ASCB Show Preview: A new universality in cell biology
Engineering, physics, computational modeling and quantitative methods are all part of this year’s ASCB special sessionsClinical Trials
Recognizing potential in RSV
Johnson & Johnson deals out $1.75B for respiratory disease company AliosStrong statement
Monoclonal antibody HIV drug succeeds in monotherapy clinical trialProgress on dementia
Intra-Cellular Therapies announces topline safety results from Phase 1/2 trial of lead dementia drug candidateEasing the pain
Improved treatment for spasticity on the horizonHope for spinal injury?
StemCells Inc. takes step toward treating cervical spinal cord injury and possibly achieving a cureMatching drug and trial options to patients
med fusion and GenomOncology recently announced a partnership to optimize treatment strategies based on the patient’s disease state and tumor profileBusiness & Government Policy
Expanding the pipeline
Endo to acquire Auxilium Pharmaceuticals in a cash-and-stock transaction for approximately $2.6 billionA ‘win-win’ in women’s health
AMAG Pharmaceuticals to acquire Lumara Health, propelling company into women’s healthAbbVie aborts plan to acquire Shire
After U.S. tax officials begin to put up roadblocks to inversion deals, deal falls apartPatent Docs: District courts implement Supreme Court’s Actavis decision
This case illustrates the consequence of the Supreme Court’s jurisprudential decision to permit the contours of its Actavis decision to be ‘worked out’ in district and appellate courts belowOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsHorizon Discovery acquires Sage Labs
Transaction strengthens Horizon’s intellectual property with regard to CRISPR technologyDiscovery
Mining pharma’s data
Pharmaceutical companies to share data for drug design via new UC San Diego-led resourceMicrobiome to the rescue
Vaginal bacteria reveal untapped medical potential of the human microbiomeComputational combat
Researchers combine molecular, quantum mechanics to screen for HIV compoundsCreating realistic systems
Models are designed to show growth of tumor cells and effectiveness of drugs outside of the bodyA high-tech Angie’s List
New OnDeckBiotech platform connects researchers with drug discovery expertisePreclinical
Fruits of their efforts
Preclinical trials show experimental drug from seeds of Australian Blushwood tree fruit destroys cancer tumorsCutting off avenues of ESKAPE
Novel antibiotics from Melinta show in-vitro potential against resistant bacteriaOnCore marks milestones in mission to cure hepatitis B
Recently, the biopharma licensed a series of second-gen cyclophilin inhibitors for the treatment of hepatitis B and acquired a pharma with two novel drug discovery programsAn ACS agreement
MedImmune will in-license Shionogi’s biologic program for acute coronary syndromeResearch & Development
Hitting the stem cell ‘reset’
Scientists return human stem cells to earliest developmental stateCentralizing research
RNAcentral launched in September to provide unified resource for non-coding RNA dataHickory dickory dock…
Using a novel biological aging clock and tissue samples, UCLA researchers find that obesity accelerates aging of the liverA resource for cellular metabolism
Agilent teams with University of Toronto on metabolomics libraryDiagnostics
Metabolon taps Metdia for European marketing of prediabetes tests
The collaboration includes Metabolon's Quantose IR and Quantose IGT testsRemoving the ‘sword of Damocles’
MetaSite Breast diagnostic test aims to remove threat hanging over heads of most breast cancer patientsProton therapy, oncology care
IBA and Philips collaborate to personalize cancer diagnosis and treatmentAdvanced Cell Diagnostics receives major NCI grant
Award will fund development of proprietary in-situ RNA detection technology
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Reliable fluid biomarkers strategies for clinical neuroscience research
Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Understanding drug impurities: types, sources, and analytical strategies
Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Discovering cutting-edge nitrosamine analysis in pharmaceuticals
New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
